Correlation Engine 2.0
Clear Search sequence regions

  • control group (3)
  • direct (8)
  • humans (1)
  • patients (9)
  • thrombophilia (10)
  • Sizes of these terms reflect their relevance to your search.

    Direct oral anticoagulants (DOACs) are widely used for the treatment and secondary prophylaxis of venous thromboembolism (VTE). Congenital thrombophilia is a condition that predisposes to a higher incidence of VTE and often requires long-term anticoagulation for secondary prophylaxis. It is less clear the efficacy of DOACs in patients with major thrombophilia. The aim of our study was to evaluate the efficacy and safety of full and reduced DOACs dose for VTE secondary prophylaxis, in patients affected by major congenital thrombophilia compared to a control group of patients with idiopathic recurrent VTE without thrombophilia. We retrospectively evaluated consecutive patients who required long-term anticoagulation for recurrent VTE, treated with DOACs, and compared the outcomes between patients affected by major thrombophilia and the control group. The examined patients were 209. The median time of DOACs therapy was 20 months (range 6-90). Two (2.7%) thrombotic events were observed in the subset affected by major congenital thrombophilia (n = 72) and five (3.6%) in the control group (n = 137) (p 0.73). Four (5.5%) hemorrhagic events were reported in the group with major thrombophilia; 21 (15.3%) in the other group (p 0.039). No statistically significant differences were observed in terms of efficacy and safety between DOACs at full and reduced dose. Our data suggest that DOACs may be effective and safe in the secondary VTE prophylaxis in patients affected by major congenital thrombophilia, also at reduced dose. © 2022. The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI).


    Alessandra Serrao, Giovanni Manfredi Assanto, Rosaria Mormile, Mattia Brescini, Cristina Santoro, Antonio Chistolini. Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants: comparison between patients with major congenital thrombophilia versus non-thrombophilic patients. Internal and emergency medicine. 2022 Jun;17(4):1081-1085

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 35018544

    View Full Text